Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение гломерулонефрита при HCV и HBV инфекции, включая нефрит при криоглобуминемическом васкулите

Список литературы

  1. Козловская Л.В., Гордовская Н.Б., Малышко Е.Ю и др., Криоглобулинемическое поражение почек: особенности течения и лечения. Нефрол и диализ 2002; т.4, 1: 4- 8
  2. Ramos-Casals, M., Stone, J. H., Cid, M. C. & Bosch, X. The cryoglobulinaemias. Lancet 379, 348–360 (2012).
  3. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis. 2008 Sep 16; 3:25. https://doi.org/10.1186/1750-1172-3-25.
  4. Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, Zignego AL, Ferri C. Cryoglobulinaemia. Nat Rev Dis Primers. 2018 Aug 2;4(1):11. doi: 10.1038/s41572-018-0009-4.
  5. Мухин Н.А., Козловская Л.В., Малышко Е.Ю. Криоглобулинемический нефрит, ассоциированный с хронической инфекцией вируса гепатита С. Тер арх 2000; 6: 1- 5
  6. Bhimma R, Coovadia H M, Adhikari M. Hepatitis B virus-associated nephropathy in black South African children. Pediatr Nephrol. 2004;12(6):479–84. doi.org/10.1159/000077065;
  7. Xu G, Huang T. Hepatitis B virus-associated glomerular nephritis in East Asia: progress and challenges. Eur J Intern Med. 2011; 22(2):161–6. DOI: https://doi.org/10.1016/j.ejim.2010.11.005;
  8. Khedmat H, Taheri S. Hepatitis B virus-associated nephropathy: an International Data Analysis. Iran J Kidney Dis. 2010;4(2):101–5.;
  9. Li P, Wei RB, Tang L, Wu J, Zhang XG, Chen XM. Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy. Clin Nephrol. 2012;78(6):456–64. DOI 10.5414/CN107615 ;
  10. Kupin WL. Viral-associated GN: hepatitis B and other viral infections. Clin J Am Soc Nephrol. 2017;12(9):1529–33. DOI: https://doi.org/10.2215/CJN.09180816В
  11. GuptaA, QuiggRJ. Glomerular Diseases Associated With Hepatitis B and C. Adv Chronic Kidney Dis. 2015 Sep;22(5):343-51. doi: 10.1053/j.ackd.2015.06.003.
  12. Абдурахманов Д.Т. Хронический гепатит В и D. М: ГЭОТАР-Медиа; 2010.
  13. Kamimura H, Setsu T, Kimura N, Yokoo T, Sakamaki A, Kamimura K, Tsuchiya A, Takamura M, Yamagiwa S, Terai S. Renal Impairment in Chronic Hepatitis B: A Review. Diseases. 2018 Jun 19;6(2). pii: E52. doi: 10.3390/diseases6020052.
  14. Chan T.M. Hepatitis B and renal disease. Curr. Hepatol. Rep. 2010;9:99–105. doi: 10.1007/s11901-010-0042-6
  15. Wang C, Ye ZY, Zeng DH, Xie FL, Qu LJ, Zheng ZY. Clinicopathological features of cryoglobulinemic glomerulonephritis associated with HBV infection: a retrospective analysis of 8 cases in China. Int J Clin Exp Pathol. 2015 Sep 1;8(9):10475-81. eCollection 2015.;
  16. Viganò M, Martin P, Cappelletti M, Fabrizi F. HBV-associated cryoglobulinemic vasculitis: remission after antiviral therapy with entecavir. Kidney Blood Press Res. 2014;39(1):65-73. doi: 10.1159/000355778.;
  17. Liver EAFTSOT: EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.;
  18. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: amodelling study. The Polaris Observatory HCV Collaborators Lancet Gastroenterol Hepatol 2017; 2: 161–76
  19. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46S5:S165–S73
  20. Arase Y, IkedaK, MurashimaN, etal. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med. 1998;37:836–840. ;
  21. El-Serag HB, Hampel H, Yeh C, et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439–1445
  22. The Polaris Observatory Collaborators. Lancet Gastroenterol Hepatol 2018; 3: 383–403
  23. Tarantino A, DeVecchi A, Montagnino G, et al. Renal disease in essential mixed cryoglobulinaemia. Long-term follow-up of 44 patients. Q J Med. 1981;50:1–30.
  24. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631–657.
  25. Tedeschi A, Baratè C, Minola E, Morra E. Cryoglobulinemia. Blood Rev 2007; 21:183– 200. doi: 10.1016/j.blre.2006.12.002.,
  26. Trejo O, Ramos-Casals M, García-Carrasco M, Yagüe J, Jiménez S, de la Red G, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001; 80:252–262. doi: 10.1097/00005792-200107000-00004.;
  27. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287–308.
  28. Милованова C.Ю. Смешанная криоглобулинемия, ассоциированная с хроническим гепатитом С: значение в развитии внепеченочных проявлений, методы лечения. : диссертация на соискание степени доктора медицинских наук: 14.01.04 / ГОУВПО "Российский университет дружбы народов". Москва, 2013
  29. Gemignani F, Melli G, Inglese C, Marbini A. Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients. J Peripher Nerv Syst. 2002 Mar;7(1):59-64.doi: 10.1046/j.1529-8027.2002.02007.x.;
  30. Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, et al. . Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC: Italian group for the study of cryoglobulinaemias. QJM (1995) 88:115–26.
  31. Morales JM, Pascual-CapdevilaJ, CampistolJM, etal.Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation. 1997;63:1634–1639.
  32. Stehman-Breen C, Alpers CE, Fleet WP, et al. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron. 1999;81:37–40
  33. Dey AK, Bhattacharya A, Majumdar A. Hepatitis C as a potential cause of IgA nephropathy. Indian J Nephrol. 2013;23:143–145.
  34. Baid S, Pascual M, Williams WW Jr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol. 1999;10:146–153.
  35. Markowitz GS, Cheng JT, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J am Soc Nephrol. 1998;9:2244–2252
  36. Angeletti A, Cantarelli C, Cravedi P. HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents. Front Med (Lausanne). 2019 Feb 8;6:20. doi: 10.3389/fmed.2019.00020. eCollection 2019.
  37. Клинические рекомендации НОНР по ХБП https://rusnephrology.org/wp- content/uploads/2020/12/CKD_final.pdf
  38. Chen YP, Cheng H, Rui HL, Dong HR. Cryoglobulinemic vasculitis and glomerulonephritis: concerns in clinical practice. Chin Med J (Engl). 2019 Jul 20;132(14):1723-1732. doi: 10.1097/CM9.0000000000000325.
  39. Vermeersch P, Gijbels K, Marien G, et al.A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. Clin Chem 2008; 54: 39–43
  40. Motyckova G, Murali M. Am J Hematol. Laboratory testing for cryoglobulins. 2011 Jun;86(6):500-2. doi: 10.1002/ajh.22023.
  41. Gulli F, Basile U, Gragnani L, Fognani E, Napodano C, Colacicco L, Miele L, De Matthaeis N, Cattani P, Zignego AL, Rapaccini GL. Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders. Dig Liver Dis. 2016 Aug;48(8):927–33. https://doi.org/10.1016/j.dld.2016.05.013.
  42. Rui HL, Cheng H, Wang GQ, Xu XY, Luan HX, Yang M, et al.Clinical and pathological analysis of 30 cases of cryoglobulinemia-associated glomerulonephritis (in Chinese). Chin J Pract Intern Med 2018;38:553–558. doi: 10.19538/j.nk 2018060116;
  43. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. Translational Nephrology C, Agarwal A, et al.KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 8: 91-165, 2018
  44. Кupin WL. Viral-Associated GN: Hepatitis C and HIV. Clin J Am Soc Nephrol. 2017;12:1337–1342.
  45. Sabry A, E-Agroudy A, Sheashaa H, El-Husseini A, Mohamed Taha N, Elbaz M, Sobh M. HCV associated glomerulopathy in Egyptian patients: clinicopathological analysis. Virology.2005;334:10–16.;
  46. Fornasieri A, Tazzari S, Li M, Armelloni S, Tarelli LT, Sessa A, D'Amico G. Electron microscopy study of genesis and dynamics of immunodeposition in IgMk-IgG cryoglobulin-induced glomerulonephritis in mice. Am J Kidney Dis. 1998 Mar;31(3):435-42. doi: 10.1053/ajkd.1998.v31.pm9506680
  47. Cacoub P, Si Ahmed SN, Ferfar Y, et al. Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis [e-pub ahead of print]. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2018.05.021.
  48. Rutledge SM, Chung RT, Sise ME. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodial Int. 2018 Apr;22 Suppl 1:S81-S96. doi: 10.1111/hdi.12649.
  49. Bonacci M, Lens S, Marino Z, et al. Long-term outcomes of patients with HCV- associated cryoglobulinemic vasculitis after virologic cure [e-pub ahead of print]. Gastroenterology. 2018;155:311–315.
  50. Bonacci M, Lens S, Londono MC et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017;15:575–583.
  51. Gragnani L, Visentini M, Fognani E, et al. Prospective study of guidelinetailored therapy with direct-acting antivirals for hepatitis C virus associated mixed cryoglobulinemia. Hepatology. 2016;64:1473–1482.
  52. Cacoub P, Vautier M, Desbois AC, et al. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era. Liver Int. 2017;37:1805–1813.
  53. Rutledge SM, Chung RT, Sise ME. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. HemodialInt. 2018 Apr; 22 Suppl 1:S81-S96. doi: 10.1111/hdi.12649.
  54. Bonacci M, Lens S, Marino Z, et al. Long-term outcomes of patients with HCV- associated cryoglobulinemic vasculitis after virologic cure [e-pub ahead of print]. Gastroenterology. 2018;155:311–315.
  55. Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618-2628.
  56. Bruchfeld A, Roth D, Martin P,et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infec- tion and stage 4-5 chronic kidney disease: clinical, vi- rological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double- blind, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2017;2:585-594
  57. Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377:1448-14552.
  58. Cox-North P, Hawkins KL, Rossiter ST, Hawley MN, Bhattacharya R, Landis CS. Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun 2017;1:248–255.
  59. Desnoyer A, Pospai D, Le MP, Gervais A, Heurgue-Berlot A, Laradi A, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 2016;65:40–47]
  60. Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol 2019;71:660–665.
  61. Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent Hepatitis C Virus– Associated Cryoglobulinemic Vasculitis Following Virus Eradication After Direct- Acting Antiviral Therapy. Hepatology. 2017;65(5):1770-71. doi: 10.1002/hep.28981
  62. Zubkin ML, Abdurakhmanov DT, Sagalova OI, Bakulin IG, Maevskaya MV, Ivashkin VT. Persistent mixed cryoglobulinemia after successful antiviral treatment of chronic hepatitis C virus infection: What's the next? Scandinavian J Gastroenterology. 2018;53(7):883-4. doi: 10. 1080/00365521.2018.1477988
  63. Quigg RJ, Brathwaite M, Gardner DF, Gretch DR, Ruddy S. Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Am J Kidney Dis. 1995;25:798-800.;
  64. Marson P, Monti G, Montani F, Riva A, Mascia MT, Castelnovo L, Filippini D, Capuzzo E, Moretto M, D'Alessandri G, Marenchino D, Zani R, Fraticelli P, Ferri C, Quartuccio L, De Silvestro G, Oreni L, Accorsi P, Galli M. Apheresis treatment of cryoglobulinemic vasculitis: A multicentre cohort study of 159 patients. Transfus Apher Sci. 2018 Oct;57(5):639-645. doi: 10.1016/j.transci.2018.06.005.
  65. TarantinoA, CampiseM, BanfiG, etal. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. KidneyInt. 1995;47: 618–623.
  66. Pietrogrande M, DeVita S, Zignego A, Pioltelli P, Sansonno D, Sollima S et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus‐infected patients. Autoimmun Rev 2011; 10: 444–54.,
  67. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F et al. Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116: 335–42.,
  68. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012 Mar;64(3):843-53. doi: 10.1002/art.34331.
  69. Mazzaro C, DalMaso L, Urraro T, Mauro E, Castelnovo L, Casarin P, etal. Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delleCrioglobulinemie – GISC. Dig Liver Dis 2016;48:780– 784
  70. De Virgilio A, Greco A, Magliulo G, Gallo A, Ruoppolo G, Conte M, et al. Polyarteritis nodosa: A contemporary overview. Autoimmun Rev 2016;15:564–5703.
  71. Elewa U., Sandri A.M., Kim W.R., Fervenza F.C. Treatment of hepatitis B virus- associated nephropathy. Nephron Clin. Pract. 2011;119:c41–c49. doi: 10.1159/000324652.
  72. Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005;68:1750-8.DOI: 10.1111/j.1523- 1755.2005.00591.x
  73. Ng YY, Yang WC, Lee ST. Long-term lamivudine therapy in hepatitis B-associated membranous nephropathy? Kidney Int 2006;69:776. DOI: 10.1038/ sj.ki.5000171
  74. Wang L, Xie B, Zheng Q, Xu L, Ye Z. Efficacy of entecavir in treating hepatitis B virus- associated membranous nephropathy. Rev Esp Enferm Dig. 2020 Nov;112(11):843-849. doi: 10.17235/reed.2020.6762/2019.
  75. Du W, Zheng Z, Han S, Ma S, Chen S. HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review. BMC Infect Dis. 2013 Aug 27;13:394. doi: 10.1186/1471-2334-13-394.
  76. Zhang Y, Chen S, Yang D, Liu J, Zhang X, Yang X, Han H, Yang D. Efficacy and Safety of Long-Term Corticosteroid Monotherapyin 26 Cases of Nephrotic Syndromewith Biopsy-Proven Membranous Nephropathy Induced by Seronegative Hepatitis B Virus-Associated Glomerulonephritis. Nephron. 2021 Feb 9:1-10.doi: 10.1159/000511467.
  77. Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, Cohen P; French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005 Sep;84(5):313-322. doi: 10.1097/01.md.0000180792.80212.5e.
  78. Enomoto M, Nakanishi T, Ishii M, Tamori A, Kawada N. Entecavir to treat hepatitis B- associated cryoglobulinemic vasculitis. Ann Intern Med. 2008;149(12):912–913. doi: 10.7326/0003-4819-149-12-200812160-00019.
  79. Enriquez R, Sirvent AE, Andrada E, Escolano C, Rodriguez JC, Millan I, Gutierrez F, Amoros F. Cryoglobulinemic glomerulonephritis in chronic hepatitis B infection. Ren Fail. 2010;32(4):518–522. doi: 10.3109/08860221003675252
  80. Terrier B, Semoun O, Saadoun D, Sene D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis c virus infection and systemic vasculitis. Arthritis Rheum. (2011) 63:1748–57. 10.1002/art.30319
  81. Lai TS, Lee MH, Yang HI, You SL, Lu SN, Wang LY, et al. . Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: reveal-HCV study. Hepatology (2017) 66:784–93. 10.1002/hep.29192
  82. Yoo JJ, Lee JH, Yoon JH, Lee M, Lee DH, Cho Y, Jang ES, Cho EJ, Yu SJ, Kim YJ, Lee HS. Gastroenterol Res Hepatitis B virus-related glomerulonephritis: not a predominant cause of proteinuria in korean patients with chronic hepatitis B. Pract. 2015;2015:126532. doi: 10.1155/2015/126532.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*